Belite Bio
Belite Bio
BLTE
NASDAQ
67.44
USD
0.00%
About
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients. In STGD1, it is developing LBS-008 as once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4 which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products.
Its product candidate also includes LBS-009 an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 18.1K |
| Three Month Average Volume | 968.6K |
| High Low | |
| Fifty-Two Week High | 50.66 USD |
| Fifty-Two Week Low | 26.65 USD |
| Fifty-Two Week High Date | 19 Jul 2024 |
| Fifty-Two Week Low Date | 08 Sep 2023 |
| Price and Volume | |
| Current Price | 48.68 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.26% |
| Thirteen Week Relative Price Change | -7.08% |
| Twenty-Six Week Relative Price Change | -4.83% |
| Fifty-Two Week Relative Price Change | 13.10% |
| Year-to-Date Relative Price Change | -10.15% |
| Price Change | |
| One Day Price Change | 0.45% |
| Thirteen Week Price Change | -0.55% |
| Twenty-Six Week Price Change | 4.64% |
| Five Day Price Change | -0.47% |
| Fifty-Two Week Price Change | 41.72% |
| Year-to-Date Price Change | 6.40% |
| Month-to-Date Price Change | -1.66% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.10232 USD |
| Book Value Per Share (Most Recent Quarter) | 3.74336 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.10232 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.74336 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.26984 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.18946 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.22531 USD |
| Normalized (Last Fiscal Year) | -1.18946 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.18946 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.22531 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.18946 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.22531 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.02431 USD |
| Cash Per Share (Most Recent Quarter) | -99999.99 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.18423 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -18.51% |
| EPS Change (Trailing Twelve Months) | -12.70% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 16 |
| Price to Tangible Book (Most Recent Quarter) | 13 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 0 |
| Net Debt (Last Fiscal Year) | -88,157,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 16 |
| Price to Book (Most Recent Quarter) | 13 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 25 |
| Current Ratio (Most Recent Quarter) | -100,000 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -29,900,000 |
| Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -45.54% |
| Return on Assets (Trailing Twelve Months) | -39.40% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -47.95% |
| Return on Equity (Trailing Twelve Months) | -41.44% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -47.50% |
| Return on Investment (Trailing Twelve Months) | -39.40% |
| Return on Investment (5 Year) | -99,999.99% |